Craft

Entrada Therapeutics

Stock Price

$17.3

2024-10-29

Market Capitalization

$642.8 M

2024-10-29

Revenue

$25.4 M

FY, 2025

Entrada Therapeutics Summary

Company Summary

Overview
Entrada Therapeutics is a biopharmaceutical company focusing on intracellular biologics. It utilizes its Endosomal Escape Vehicles (EEV) technology to create a pipeline of enzyme, oligonucleotide, protein, and peptide programs enabling intracellular delivery of therapeutics into a variety of organs and tissues. The company focuses on the treatment of neuromuscular disease, immunology, oncology, and diseases of the central nervous system.
Type
Public
Status
Active
Founded
2016
HQ
Boston, MA, US | view all locations
Website
https://www.entradatx.com/
Cybersecurity rating
Sectors

Key People

  • Nathan J. Dowden

    Nathan J. Dowden, Chief Operating Officer

  • Natarajan Sethuraman

    Natarajan Sethuraman, Chief Scientific Officer

  • Kory Wentworth

    Kory Wentworth, Chief Financial Officer

  • Mary Thistle

    Mary Thistle, Director

    LocationsView all

    1 location detected

    • Boston, MA HQ

      United States

      Design Center Pl

    Entrada Therapeutics Financials

    Summary Financials

    Revenue (FY, 2025)
    $25.4M
    Net income (FY, 2025)
    ($143.8M)
    Cash (FY, 2025)
    $90.4M
    EBIT (FY, 2025)
    ($157.9M)
    Enterprise value
    $616.1M

    Footer menu